华东医药：10月27日召开董事会会议

Core Viewpoint - Huadong Medicine (SZ 000963) announced the convening of its 11th fourth board meeting on October 27, 2025, to review the proposal for revising the "Internal Audit Management System" [1] Financial Performance - For the first half of 2025, Huadong Medicine's revenue composition was as follows: Commercial brokerage and agency accounted for 68.23%, pharmaceutical manufacturing for 33.94%, medical aesthetics for 4.57%, and other businesses for 0.77%, with inter-segment eliminations at -7.5% [1] Market Capitalization - As of the report, Huadong Medicine's market capitalization stood at 70 billion yuan [1]